FdaApplication
NDA 218730
Identifiers
- fda_app_no: NDA218730
Properties
| Property | Value |
|---|---|
| applicant_name | VERTEX PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2024-12-20 |
Revenue by product
ALYFTREK
| Period | Revenue |
|---|---|
| Q2 2026 | $573.6M* |
| Q1 2026 | $424.4M* |
| Q4 2025 | $380.1M* |
| Q3 2025 | $247.0M* |
| Q2 2025 | $156.8M* |
| Q1 2025 | $53.9M* |
| Q4 2024 | $0.0M* |
| Q3 2024 | $0.0M* |
| Q2 2024 | $0.0M* |
| Q1 2024 | $0.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ALYFTREK | DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM | 50MG;20MG;EQ 4MG BASE | TABLET;ORAL |
| ALYFTREK | DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM | 125MG;50MG;EQ 10MG BASE | TABLET;ORAL |
2 products